Krebs Biochemicals: All 5 Resolutions Passed at 34th AGM on Sept 29, 2026
Krebs Biochemicals' 34th AGM on September 29, 2026, saw all five ordinary resolutions passed. These included financial statement adoption, director re-appointments, related party transactions with IPCA Laboratories, and cost auditor remuneration ratification.
The passing of resolutions related to financial statements, director appointments, and related party transactions is significant for the company's ongoing operations and governance.
All resolutions were passed, indicating shareholder approval and confidence in the company's proposals.
Krebs Biochemicals and Industries Limited announced the voting results of its 34th Annual General Meeting (AGM) held on September 29, 2026. All five ordinary resolutions placed before the shareholders were passed with the requisite majority.
The resolutions included the adoption of the Audited Balance Sheet, Statement of Profit & Loss, and Cash Flow Statement for the financial year ended March 31, 2026. Additionally, resolutions for the re-appointment of directors retiring by rotation, approval for related party transactions with IPCA Laboratories Limited, and ratification of remuneration for Cost Auditors were also passed.
The voting process, which included remote e-voting from September 25-28, 2026, and voting at the AGM (Insta Poll) on September 29, 2026, was conducted under the scrutiny of Ms. Krithika Sharma, Practicing Company Secretary. The cut-off date for determining voting entitlements was September 23, 2026.
What to do with a filing like this
Krebs Biochemicals and Industries Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krebs Biochemicals and Industries Limited. Read the original for the full detail.